Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced it will present a poster on one of the ...
Romiplostim prevents chemotherapy-induced thrombocytopenia or low platelet count, reducing bleeding risks in cancer patients ...
A CAR-NKT cell therapy targets cancer through multiple pathways, showing complete tumor elimination in preclinical models. The off-the-shelf platform reduces costs, improves access, and the therapy ...
India, March 17 -- Latest study shows a serious link between emergency room wait times and patient survival. One in ten ...
Mesothelin-targeted CAR-NKT cells leveraged three recognition mechanisms, potentially limiting antigen escape and ...
Throughout the year, the Company reported significant positive preclinical findings for SIL204 across eight KRAS mutations ...
Key Takeaways An already approved drug can protect cancer patients from bleeding due to chemoPatients taking romiplostim had ...
After their prison terms, state-designated sexual predators are placed in the Texas Civil Commitment Center, where many are ...
BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the design and ...
Healthcare organizations appear to be destroying the transcripts after a certain time, as protection against possible ...
First-in-class immune-stimulating antibody conjugate BDC-4182 in Phase 1 dose escalation study, initial clinical data expected in 3Q 2026 Cash balance of $31.8 million as of December 31, 2025 ...